anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A system and method for uniquely identifying each patient, monitoring, tracking and rescue, when admitted to any hospital, nursing home or health care providing facility. The patient identification is done by issue of a Unique Patient Identification Number (PIN). Patient monitoring is done by collection of critical parameters and comparison with a reference scale. Patient tracking is achieved by integration of the software with a suitable transmission/reception system and patient-wearable tracking device. Patient rescue is achieved by dispatch of rescue teams, as and when needed, upon notification by the system. This shall be done in a manner that protects the confidentiality and privacy of the patient. This system would help in saving the lives of at-risk and other patients, and improve patient safety. The system shall result in advance preparedness at hospitals to deal with an emergency, by providing access to patient data, speeding up diagnostics and treatment. The data collected at hospitals can be stored in a database for access. The unique PIN (Patient Identification Number) can be linked to UIN (Universal Identification Number) system for persistent patient data access over the global network. The data can only be accessed by “authorized” health care providers on a “need to know” basis.
Objective We aimed to reveal detailed on-treatment lipid profiles, lipid-related surrogate markers, and factors predicting failure to achieve the guideline-recommended lipid management goal following guideline-recommended statin treatment in Japanese patients with acute myocardial infarction (AMI). Methods Sixty AMI patients who underwent coronary intervention and had received rosuvastatin 10 mg/day since the start of their hospitalization were assessed for on-treatment lipid-related profiles, including high-sensitivity C-reactive protein, small dense low-density lipoprotein cholesterol (sd LDL-C), and lipoprotein (a), at the 12-week follow-up. Patients who failed to achieve the guideline-recommended lipid management at 12 weeks were defined as the "unachieved group." Univariate and multivariate logistic regression analyses were performed to evaluate the predictors of inclusion in the unachieved group after high-dose statin treatment. Results Despite the use of high-dose rosuvastatin, 61.7% of the enrolled AMI patients were included in the unachieved group. In addition, the unachieved group had higher sd LDL-C and lipoprotein (a) levels than the achieved group. Logistic regression analyses demonstrated that low baseline high-density lipoprotein cholesterol (HDL-C) levels and the absence of diabetes were predictors of inclusion in the unachieved group. Conclusion More than half of the Japanese AMI patients treated with rosuvastatin 10 mg/day did not achieve the guideline-recommended goal of lipid management and still had lipid-related residual risk at 12 weeks. Particular attention should be paid to patients with low baseline HDL-C levels and those without diabetes with regard to their on-treatment lipid profiles.
The invention relates to treatment of various disorders with 7,8-dihydroxyflavone and derivatives thereof. Novel compounds and methods related to the activation of the TrkB receptor are provided. The methods include administering in vivo or in vitro a therapeutically effective amount of 7,8-dihydroxyflavone or derivative thereof. Specifically, methods and compounds for the treatment of disorders including neurologic disorders, neuropsychiatric disorders, and metabolic disorders (e.g., obesity) are provided. For example, a first method is provided of treating or reducing the risk of depression, anxiety, or obesity in a subject, which includes selecting a subject with or at risk of developing depression, anxiety, or obesity, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof. A further method of promoting neuroprotection in a subject also is provided, which includes selecting a subject in need of neuroprotection, and administering to the subject a therapeutically effective amount of 7,8-dihydroxyflavone or a derivative thereof.
Objectives: This article describes how a home visit solution was developed in a co-design process between patients in treatment for severe spasticity, their caregivers and hospital nurses. The solution was developed using a participatory design approach and was based on the identified needs of the participants. Methods: We developed a home visit solution through an iterative process and a collective 'reflection-in-action' approach with patients, caregivers and healthcare professionals. Results: The study revealed the complexities of establishing new routines around home visits. The solution included a new workflow for the nurses and a new route and appointment planning tool. Conclusion: Through a participatory design approach, the users developed a home visit solution that minimised disruption to patients' daily lives and facilitated a dialogue between the nurses and the caregivers about the treatment and the patients' spasticity, which helped to adjust the treatment in line with the patient´s needs.
Participants randomized to a treatment sequence in Part 1 who received single dose placebo gel (1.97 or 3.94 mL) applied topically in error instead of active study drug and dropped out after the first treatment period in the sequence. Included in the safety assessments only.
In alternative embodiments, the invention provides compositions and methods for treating various disorders and conditions in mammals, including chronic disorders in which there is a presence of an abnormal microbiota or an abnormal distribution of microflora in the gastrointestinal tract. In alternative embodiments, the invention provides liquid preparations or formulations derived from a human fecal material (e.g., a stool) processed, e.g., filtered and/or centrifuged, such that all bacteria, fungal spores and viruses are removed, but retaining the native biologically active molecules from the fecal material and bacteriophages. In alternative embodiments, the invention provides a “rough-”, “incomplete-” or medium-filtered microbiota which still comprises native physiological components or nutritive agents for the bacteria, e.g., retains native biologically and nutritionally active components. In alternative embodiments, the invention provides a highly filtered or substantially purified microbiota in combination with, or having added back, a liquid preparation or formulation of the invention. In alternative embodiments, the invention provides compositions or formulations where the bacteria, or microbiota, component has been cultured, or cultured under anaerobic conditions, or harvested, stored and/or cultured under anaerobic conditions. In alternative embodiments, the invention provides various additives, compositions and donor restrictions for treating these disorders and conditions.
Post-traumatic striatocapsular infarction (SCI) due to lenticulostriate artery (LSA) damage is rare. Most cases reported are in children. We discuss the pathogenesis and differential diagnosis of this kind of SCI after trauma in adult patients. The most common etiology of non-traumatic SCI are an embolism from the proximal artery, cardiogenic embolism, and atherosclerotic plaque in the proximal middle cerebral artery (MCA). However, injury of the LSA after trauma may lead to hemorrhagic infarction in the basal ganglia (BG). Post-traumatic SCI due to LSA damage might be associated with hemorrhage in the BG. The main locations of these lesions are the distal perfusion area of the LSA, similar to SCI due to intracranial atherosclerotic disease affecting the MCA. Vessel wall imaging, magnetic resonance angiography, and ultrahigh-resolution computed tomography can be used for differentiating the injury mechanism in SCI following a traumatic event.
Cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), result from an impairment of bile flow that leads to the hepatic retention of bile acids, causing liver injury. Until recently, the only approved treatments for PBC were ursodeoxycholic acid (UDCA) and obeticholic acid (OCA). While these therapies slow the progression of PBC in the early stage of the disease, approximately 40% of patients respond incompletely to UDCA, and advanced cases do not respond. UDCA does not improve survival in patients with PSC, and patients often have dose-limiting pruritus reactions to OCA. Left untreated, these diseases can progress to fibrosis and cirrhosis, resulting in liver failure and the need for transplantation. These shortcomings emphasize the urgent need for alternative treatment strategies. Recently, nuclear hormone receptors have been explored as pharmacological targets for adjunct therapy because they regulate enzymes involved in bile acid metabolism and detoxification. In particular, the peroxisome proliferator-activated receptor (PPAR) has emerged as a therapeutic target for patients with PBC or PSC who experience an incomplete response to UDCA. PPARα is predominantly expressed in the liver, and it plays an essential role in the regulation of cytochrome P450 (CYP) and uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes, both of which are critical enzyme families involved in the regulation of bile acid metabolism and glucuronidation, respectively. Importantly, PPARα agonists, e.g., fenofibrate, have shown therapeutic benefits in reducing elevated markers of cholestasis in patients with PBC and PSC, and elafibranor, the first PPAR (dual α, β/δ) agonist, has been FDA-approved for the second-line treatment of PBC. Additionally, newer PPAR agonists that target various PPAR isoforms (β/δ, γ) are under development as an adjunct therapy for PBC or PSC, although their impact on glucuronidation pathways are less characterized. This review will focus on PPAR-mediated bile acid glucuronidation as a therapeutic pathway to improve outcomes for patients with PBC and PSC.
In one embodiment, the present invention is directed to a first oligonucleotide comprising the sequence of or derived from 5'-CTAGGGCGGGCGGGACTCACCTAC-3' or the nucleic acid sequence complementary thereto. The first oligonucleotide can be used with a nucleic acid of between 15 and 30 nucleotides that does not comprise the sequence of the first oligonucleotide and is found in the region from Vβ to Jβ of the Vβ13.1 gene in Vβ13.1 T cells, wherein the sequences of the oligonucleotide and the nucleic acid are not found on the same strand of the Vβ13.1 gene pair, to amplify a portion of the Vβ13.1 gene. Alternatively, the first oligonucleotide can be used with a labeling moiety in methods of detecting a LGRAGLTY motif found in T cell receptors of Vβ13.1 T cells. This motif is associated with autoimmune diseases, such as multiple sclerosis (MS). Once the motif is detected, the autoimmune disease can be treated or its progress monitored. The autoimmune disease can be treated by administering a peptide comprising the LGRAGLTY motif.
Subjects received CIN-107 1 mg tablets, administered orally once daily for 12 weeks. Subjects continued taking stable anti-hypertensive regimen throughout the study.
FIELD: molecular biotechnology, medicine. SUBSTANCE: invention presents a reconstructed human anti-HM 1.24 antibody where C-site of H- and L-chain and V-site of H- and L-chain comprise human FR and CDR is prepared from anti-HM 1.24 monoclonal antibody and CDR shows low antigenicity. Reconstructed human anti-HM 1.24 antibody is prepared by transformation of Cell-host with expressing vector that comprises DNA encoding antibody. Human anti-HM 1.24 antibody is used as an active component for treatment of myeloma. EFFECT: improved method of preparing, valuable antitumor property. 17 cl, 40 dwg, 6 tbl
Caregivers in this group will participate in 16 sessions of online therapy delivered through a combination of asynchronous material and virtual support groups. These sessions will include Dialectical Behaviour Therapy (DBT) and parenting training. This group will be asked to evaluate the program with surveys completed pre-program, immediately post-program, and three months post-program. This group will also be invited to complete weekly surveys expected to take 5 minutes.
Lactose intolerance is due to lactase deficiency. Lactase is a Sulfur-containing enzyme. Sulfur, mixed with molasses, has been used as a laxative. The study included 11 patients, 7 men and 4 women, with severe lactose intolerance for over 1 year; intake of milk and milk products caused diarrhea, abdominal pain, distention, bloating, and flatulence within 15 minutes to 1 hour. After confirmation of lactose intolerance by a lactose-free diet for 1 week, the patients were placed simultaneously on a lactose-free diet and Sublimed Sulfur 200 mg, 1 capsule orally pc bid for 15 days, after which they initiated a regular diet including milk and milk products and continued Sublimed Sulfur 200 mg, 1 capsule orally pc bid for a further 30 days. Patients with diarrhea from causes other than milk and milk products were excluded from the study. The patients did not take Beta-D-galactosidase during the study. During the third week of therapy with Sublimed Sulfur, the 11 patients became symptom-free for diarrhea, abdominal pain, bloating and flatulence; and remained lactose tolerant without further treatment. One of the 11 patients relapsed after 57 weeks; lactose tolerance was restored to this patient after another course of treatment with Sublimed Sulfur; another patient relapsed after 14 weeks and did not receive further treatment. There were no side-effects to therapy with Sublimed Sulfur. A regimen of therapy with Sublimed Sulfur restores lactose tolerance in subjects with lactose intolerance without causing side effects.
This is a multi-center randomized clinical trial designed to test whether a regenerative endodontic procedure using tissue engineering principles (REGENDO), or a revascularization (REVASC) endodontic procedure, when compared to the standard apexification treatment using mineral trioxide aggregate barrier-MTA apexification (APEX), produces a significantly better composite clinical outcome for the treatment of immature permanent teeth with pulpal necrosis. This study will use an antibiotic mixture called Triple Antibiotic Paste (TAP), consisting of ciprofloxacin, metronidazole and minocycline, in the tooth for disinfection of the root canal in study arms REGENDO and REVASC. The FDA has issued an Investigational New Drug (IND) number allowing use of the triple antibiotic mixture in this trial. Other dental materials used in this study have already been FDA approved for use in humans to provide a matrix for the promotion of tissue growth in the root canal space. The study will also attempt to identify the type of bacteria within the root canal space and surrounding tissues by analyzing a small sample collected on a cotton-tip applicator. This clinical trial hopes to determine which of the three treatment methods helps the tooth to grow stronger and survive for at least two years after treatment.
Radiation therapy (RT), with a relevant integration of external beam radiotherapy (EBRT) and intracavitary brachytherapy (ICBT), is an important part in the treatment of cervical cancer. Even though concurrent chemoradiation therapy (CCRT) improves the control of locoregional recurrence and distant metastasis for locally advanced disease, the role of RT remains important and essential. ICBT is an essential component of RT and has been used to deliver a high localized dose to the primary cervical lesion and adjacent parametria with an attempt to minimize dose to nearby normal tissues. The conventional point-based dose prescription systems have been applied for decades. Incorporation of modern imaging techniques, namely computerized tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) to ICBT, enable radiation oncologists to individualize treatment volumes but yet, not applicable for routine practice. Point A, since defined by Tod and Meredith in 1938 and revised in 1953, has been widely accepted as a sacrosanct reference point for dose prescription of ICBT. Point A was defined as a point 2 cm above the cervical os and 2 cm apart from os on the line perpendicular to uterine axis. It is a hypothetical point representing the crossover of the ureter and uterine artery, located in the paracervical triangle, and is considered as a critical point for radiation tolerance. This definition of point A provides an easy way to prescribe dose in ICBT and integrate with EBRT. However, its dosimetry according to orthogonal radiographs would depend solely on the applicator geometry but not the individual tumor volume or location. The International Commission on Radiation Units and Measurements (ICRU) report 38 proposed a set of guidelines for uniform reporting. Reporting of the dimensions of reference volumes still depends on the geometry of applied applicator and remains difficult for reporting of ICBT. Thus, point A is still used as a reference point for dose prescription and for correlating the treatment outcome in clinical trials. CCRT has been considered as a standard of care for locally advanced cervical cancer. To further dissect the patient population, which may have a benefit of less morbidity from CCRT, but not radical surgery plus subsequent RT, the sampling of pelvic and paraaortic lymph nodes prior to decision of intended surgery has been utilized by performing laparoscopy or laparotomy for stages IB and IIA. Moreover, this sampling procedure can also provide a pathological proof and delineation of lymph nodes at risk for an important reference of RT field design. During sampling procedures, we observed that the point crossing over the ureter and uterine artery could be visualized and marked by using hemoclips. Therefore, the anatomic position of point A could be visualized on the orthogonal films after closure of abdominal wound. In this study, we attempt to compare the location of and the radiation doses to anatomic point A (APA) and hypothetical point A (HPA) during fractionated ICBT.
Each forearm of the subject will be divided into two squared areas (4x4 cm). The provocations of three areas will be performed with 100 µg of papain by SPT lancets. To assess the potential importance of repeated pricks, papain will be applied by 1, 5 or 25 SPT pricks thought the skin. The last area will be exposed to cowage spicules (made chemically inert by autoclaving) soaked in 5 mg/ml papain solution.
610,105. Valve amplifying circuits. STANDARD TELEPHONES & CABLES, Ltd. March 23, 1946, No. 9021. Convention date, April 14, 1945. [Class 40 (vi)] Instability in a negative feed-back amplifier is prevented by combining with the normal feed-back voltage, an additional voltage such that the resultant is a net feed-back voltage substantially 180 degrees out of phase with the input voltage over the whole of the frequency range. In this way the overall amplification is directly proportional to the amplification of the forward path and the effective input voltage is in phase and in a constant ratio to the signal input over a range of frequencies. In Fig. 2, V1 is the input voltage without feed-back, V2 the normal feed-back voltage and V the net input voltage with feed-back, an additional voltage V3 being added so that the resultant feed-back voltage V4 is 180 degrees out of phase with V1 and the system is stable. In Fig. 1, the main and correlative amplifiers 9, 21 have identical gain and phase-frequency characteristics so that the voltages V1 and Vc across potentiometers 10 and 22 are in phase and equal in amplitude. The valves 26, 27 comprise a phase mixer so that when voltage Vc and V (Fig. 4) are applied to their grids, a resultant voltage V3 appears at their common anode circuit, the voltage being amplified and applied to the input circuit of the main amplifier as a voltage V3. By plotting a polar diagram of the magnitude and phase angle of ÁB over a given range of frequencies, the frequency at which # (the phase angle of ÁB) is 180 degrees can be found. A voltage at this frequency is applied to the input of the main amplifier and potentiometer 22 is adjusted until the output of the phase mixer is zero, i.e. Vc is in phase opposition to V. From the polar diagram of ÁB the ratio of the scalar value of ÁB at # = 0 degrees and # = 180 degrees can be determined. A voltage is fed into the input of the main amplifier at the frequencies for which # =0 degrees and # =180 degrees and the contact 43 is adjusted until the ratio of the output voltages of the main amplifier is equal to the above-mentioned ratio of the two scalar values of ÁB. In a modification, Fig. 7 (not shown), a multi-grid mixing valve is used in the input circuit of the main amplifier to combine the voltages V1, V2 and V3.
Disclosed are systems and methods for improving interactions with and between computers in content communicating, rendering, generating, hosting and/or providing systems supported by or configured with computing devices, servers and/or platforms. The systems interact to improve the quality of data used in processing interactions between or among processors in such systems for determining obscured portions of displayed digital content. The disclosed method and apparatus involve acquiring and recording coordinates of each pixel in a digital image, and marking the pixels located at a boundary of the image as boundary pixels. The pixels located at a first region block are extracted and marked as obstruction pixels. An obstructed cutting space area corresponding to each pixel is determined based on positional relations of each pixel in the image. An image obstruction score is calculated based on the cutting space areas and utilized for rendering the pixels of the image.
The present invention relates to female medicinal wine for nursing faces and preventing ageing. The present invention takes peach flowers, lotus flowers, Chinese rose flowers, rose flowers, chrysanthemum flowers, ganodermas, Chinese photinia leaves, fructus lycii, dodder seeds, angelica, solomonseal rhizome, pilose asiabell roots, nutagrass flatsedge rhizome, fragrant solomonseal rhizome, longan, hundred flowers, broomrape, cinnamon, fructuses as raw materials. After soaked in Shaoxing yellow wine of 18 DEG, the raw materials are deslagged, and then, are added with red wine of 11 DEG. The raw materials, the Shaoxing yellow wine of 18 DEG and the red wine of 11 DEG are mixed and sealed. The medicinal wine has efficiency of menstruation regulation, face nursing, spleen strengthening, stomach regulation, liver nutrition and kidney replenishment. The medicinal wine makes faces sanguineness, refined and white, blacks hair, thinns bodies and prevents ageing.